Ophthalmic Markets

The total global ophthalmology market targeted by Icon Bioscience, Inc. is estimated to be in excess of $20 billion and expected to rise.  In addition, the global population of diabetes is expected to increase significantly in the upcoming decades.  Intraocular injections have already become state of the art for controlling and treating complications arising from diabetic retinopathy.

As the global population ages, the prevalence of more age related diseases, such as glaucoma and macular degeneration, will continue to increase exponentially.  Topical therapy, in the form of daily eye drops, will be replaced with sustained intraocular delivery.  Also, we believe second-generation treatment of macular degeneration will employ intraocular injections of compounds that will last months; obviating the need of more frequent, and costly, monthly injections.

IBI’s Verisome® platform has the ability to adapt to current and emerging markets by increasing efficacy of existing medicines, eliminating inefficient topical therapy and avoiding systemic toxicity.  The platform offers the unique capability of customized delivery of the therapeutic agent to the target tissue.


My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.